Long-Term Survival after Percutaneous Image-Guided Microwave Ablation of Pathologically Proven Renal Cell Carcinoma

To determine the technical success, long-term overall survival (OS), cancer-specific survival (CSS), and local tumor progression-free survival (LTPFS) of patients who underwent percutaneous microwave ablation (MWA) of renal cell carcinoma (RCC).

This institutional review board (IRB)-approved, Health Insurance Portability and Accountability Act (HIPAA)-compliant study cohort included patients who underwent CT and contrast-enhanced ultrasound (US) guided percutaneous MWA between 2013 and 2017 of biopsy-proven RCC. Patient demographics, tumor characteristics, and technical outcomes were compiled, and the OS, CSS, and LTPFS were derived with Kaplan-Meier analysis and log-rank test to evaluate differences. Complications were classified per the Clavien-Dindo system. Logistic regression was used for categorical outcomes, the χ² test was used for categorical outcomes excluding repeated measures at the patient level, and the paired t test was used for evaluating differences in preablative and postablative estimated glomerular filtration rate.

The study cohort comprised 86 biopsy-proven RCCs from 81 patients (mean age, 67.6 years [SD ± 16.9]), with a median follow-up of 76.8 months. Overall, primary, and secondary technical success were 100% (86/86), 98% (84/86), and 100% (10/10), respectively. The 10-year OS, CSS, and LTPFS rates were 76%, 85%, and 83%, respectively. The T1b subcohort 8-year LTPFS rate was lower than the T1a subcohort (P = .003). The preablative and 2- to 3-year postablative estimated glomerular filtration rate (58.5 vs 58.4 mL/min/1.73 m²) were stable (P = .932). There was a 2% overall incidence of complications, all Grade I.

Percutaneous image-guided MWA of T1 RCC was associated with excellent long-term OS, CSS, and LTPFS, supporting MWA as an effective treatment option.